Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridging Radiation Therapy With Oral Vancomycin for B-cell Lymphomas Undergoing CAR-T Therapy
NCT07478848Phase 1Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- May 2026
- Primary completion
- Jan 2029
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vancomycin in diffuse large B-cell lymphoma (DLBCL), sponsored by Abramson Cancer Center. Primary endpoints: Cytokine release syndrome at 28 days, Severe adverse events at 28 days and 2 more. Started May 2026; status: recruiting.
02
Drugs
vancomycin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07478848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07478848.